Reuters logo
BRIEF-Ocular Therapeutix announces results for Phase 3 clinical trial of DEXTENZA
January 4, 2017 / 1:15 PM / 9 months ago

BRIEF-Ocular Therapeutix announces results for Phase 3 clinical trial of DEXTENZA

Jan 4 (Reuters) - Ocular Therapeutix Inc :

* Ocular therapeutix(tm) announces additional successful results for Phase 3 clinical trial of dextenza(tm)

* Ocular therapeutix inc - statistically significant secondary endpoint of absence of ocular flare confirms further evidence of reduction of inflammation

* Ocular therapeutix inc - secondary endpoint was statistically superior to placebo at all measured time points

* Ocular therapeutix - dextenza has exhibited a favorable safety profile and has been well tolerated in all clinical trials, regardless of indication

* Ocular therapeutix inc - plans to resubmit nda to fda for dextenza for treatment of ocular pain occurring after ophthalmic surgery early in q1 of 2017

* Ocular therapeutix inc - intends to submit supplemental nda for dextenza to broaden its label to include an indication for post-surgical inflammation Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below